Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 4;12:803726. doi: 10.3389/fimmu.2021.803726

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Matos, Peter, Weich, Peuker, Schoenhammer, Roider, Ghimire, Babl, Decking, Güllstorf, Kröger, Hammon, Herr, Stark, Heid, Renner, Holler and Kreutz

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Impact of ATG treatment on 25(OH)D3 and 1,25(OH)2D3 circulating serum levels of patients undergoing hematopoietic stem cell transplantation Panel (A) depicts the median serum 25-hydroxyvitamin D3 levels followed over time in association with ATG treatment for the discovery cohort. In panel (B), the median serum 1,25(OH)2D3 level is presented. Panel (C) depicts the median serum 25(OH)D3 levels from days -2 to 7 around HSCT of patients receiving ATG and patients that did not received ATG. In panel (D), the median serum 1,25(OH)2D3 level is presented. Numbers indicate median serum 25(OH)D3 and 1,25(OH)2D3 values, error bars indicate 95% confidence interval. Statistical analysis was performed with Mann-Whitney-U test, two-tailed (**p < 0.01). In (E, F) the distribution of patients below and above the calculated cut-off is shown, in relation to ATG treatment for the cohorts with high and low/no vitamin D3 supplementation, respectively.